

Aidan Hollis

List of Publications by Citations

Source: <https://exaly.com/author-pdf/59860/aidan-hollis-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63

papers

968

citations

17

h-index

30

g-index

66

ext. papers

1,193

ext. citations

5

avg, IF

4.86

L-index

#	Paper	IF	Citations
63	Co-authorship and the output of academic economists. <i>Labour Economics</i> , 2001 , 8, 503-530	1.4	109
62	Preserving antibiotics, rationally. <i>New England Journal of Medicine</i> , 2013 , 369, 2474-6	59.2	96
61	Microcredit: What can we learn from the past?. <i>World Development</i> , 1998 , 26, 1875-1891	5.5	73
60	The large-scale integration of wind generation: Impacts on price, reliability and dispatchable conventional suppliers. <i>Energy Policy</i> , 2010 , 38, 3837-3846	7.2	55
59	The importance of being first: evidence from Canadian generic pharmaceuticals. <i>Health Economics (United Kingdom)</i> , 2002 , 11, 723-34	2.4	53
58	An economic justification for open access to essential medicine patents in developing countries. <i>Journal of Law, Medicine and Ethics</i> , 2009 , 37, 184-208	1.2	52
57	The Health Impact Fund: incentives for improving access to medicines. <i>Lancet, The</i> , 2010 , 375, 166-9	4.0	51
56	Estimating the clinical cost of drug development for orphan versus non-orphan drugs. <i>Orphanet Journal of Rare Diseases</i> , 2019 , 14, 12	4.2	41
55	Impact of isolation precautions on quality of life: a meta-analysis. <i>Journal of Hospital Infection</i> , 2020 , 105, 35-42	6.9	39
54	The life-cycle of a microfinance institution: the Irish loan funds. <i>Journal of Economic Behavior and Organization</i> , 2001 , 46, 291-311	1.6	35
53	A contractual approach to the gray market. <i>International Review of Law and Economics</i> , 1999 , 19, 1-21	0.8	35
52	The Anti-Competitive Effects of Brand-Controlled "Pseudo-Generics" in the Canadian Pharmaceutical Market. <i>Canadian Public Policy/Analyse De Politiques</i> , 2003 , 29, 21	2.5	29
51	Microcredit in Prefamine Ireland. <i>Explorations in Economic History</i> , 1998 , 35, 347-380	1.3	28
50	Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus. <i>Journal of Antibiotics</i> , 2020 , 73, 421-428	3.7	25
49	Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach. <i>Orphanet Journal of Rare Diseases</i> , 2013 , 8, 180	4.2	22
48	Microfinance and Famine: The Irish Loan Funds during the Great Famine. <i>World Development</i> , 2004 , 32, 1509-1523	5.5	17
47	How do Brands Down Generics Affect Pharmaceutical Prices?. <i>Review of Industrial Organization</i> , 2005 , 27, 329-350	1	17

46	Price-cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals. <i>Health Economics (United Kingdom)</i> , 2015 , 24, 966-77	2.4	12
45	Sustainable Financing of Innovative Therapies: A Review of Approaches. <i>Pharmacoeconomics</i> , 2016 , 34, 971-80	4.4	12
44	Attitudes, behaviours and barriers to public health measures for COVID-19: a survey to inform public health messaging. <i>BMC Public Health</i> , 2021 , 21, 765	4.1	12
43	Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021 , 14, 3	3.2	12
42	Delays in the submission of new drugs in Canada. <i>Cmaj</i> , 2015 , 187, E47-E51	3.5	11
41	Comment on "The economics of follow-on drug research and development: trends in entry rates and the timing of development". <i>Pharmacoeconomics</i> , 2005 , 23, 1187-92; discussion 1193-202	4.4	10
40	The Role of Local Depositors in Controlling Expenses in Small-Scale Financial Intermediation: An Empirical Analysis. <i>Economica</i> , 2007 , 74, 713-735	1.2	9
39	Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy. <i>Cmaj</i> , 2015 , 187, 422-425	3.5	8
38	Industrial Concentration, Output, and Trade: An Empirical Exploration. <i>Review of Industrial Organization</i> , 2003 , 22, 103-119	1	8
37	Governance of electricity transmission systems. <i>Energy Economics</i> , 2005 , 27, 237-255	8.3	8
36	Strategic Implications of Learning by Doing. <i>International Journal of the Economics of Business</i> , 2002 , 9, 157-174	0.9	8
35	Synthetic biology: ensuring the greatest global value. <i>Systems and Synthetic Biology</i> , 2013 , 7, 99-105		7
34	A Critique in Need of Critique. <i>Public Health Ethics</i> , 2010 , 3, 178-185	1.8	7
33	Preliminary Injunctions and Damage Rules in Patent Law. <i>Journal of Economics and Management Strategy</i> , 2007 , 16, 385-405	1.9	6
32	How parallel trade affects drug policies and prices in Canada and the United States. <i>American Journal of Law and Medicine</i> , 2006 , 32, 193-217	0.5	6
31	Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi. <i>Healthcare Policy</i> , 2019 , 15, 70-80	4.1	5
30	Combating Antibiotic Resistance Through the Health Impact Fund. <i>SSRN Electronic Journal</i> ,	1	5
29	The path of least resistance: paying for antibiotics in non-human uses. <i>Health Policy</i> , 2014 , 118, 264-70	3.2	4

28	Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics. <i>International Journal of the Economics of Business</i> , 2015 , 22, 201-217	0.9	3
27	Drugs for Neglected Diseases: New Incentives for Innovation	75-90	3
26	Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem. <i>Healthcare Policy</i> , 2015 , 11, 10-4	1.1	3
25	How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?. <i>Health Policy</i> , 2019 , 123, 1251-1258 ^{3,2}		3
24	Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based?. <i>Value in Health</i> , 2021 , 24, 1328-1334	3.3	3
23	How cheap are Canada's drugs really?. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2004 , 7, 215-6	3.4	3
22	A comparison of mechanisms for setting generic drug prices in Canada. <i>Journal of Generic Medicines</i> , 2017 , 13, 19-27	0.2	2
21	Generic drugs in Canada: an examination of tiered pricing. <i>Cmaj</i> , 2015 , 187, 1033-1034	3.5	2
20	Competition policy in open economies. <i>International Economic Journal</i> , 2004 , 18, 179-193	0.8	2
19	Combating Antibiotic Resistance Through the Health Impact Fund	2013 , 318-338	2
18	Market concentration of new antibiotic sales. <i>Journal of Antibiotics</i> , 2021 , 74, 421-423	3.7	2
17	The impact of pharmaceutical rebates on patients' drug expenditures. <i>Cmaj</i> , 2019 , 191, E308-E312	3.5	1
16	Patient income and health innovation. <i>Health Economics (United Kingdom)</i> , 2020 , 29, 1795-1803	2.4	1
15	Epilogue: New drugs for neglected diseases. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2011 , 20, 329-34	0.9	1
14	Microcredit in Pre-Famine Ireland. <i>SSRN Electronic Journal</i> ,	1	1
13	Beyond Benefit Sharing: Steps Towards Realizing the Human Right to Health	2013 , 203-216	1
12	Global clinical trial mobilization for COVID-19: higher, faster, stronger. <i>Drug Discovery Today</i> , 2020 , 25, 1801-1806	8.8	1
11	Factors associated with drug shortages in Canada: a retrospective cohort study. <i>CMAJ Open</i> , 2020 , 8, E535-E544	2.5	1

10	Pre-market development times for innovative vaccines - to what extent are the COVID-19 vaccines outliers?. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	1
9	New drug development. <i>Lancet, The</i> , 2011 , 377, 901-2	4.0	0
8	The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergencies. <i>PLoS ONE</i> , 2021 , 16, e0258013	3.7	0
7	An Irish Working Class: Explorations in Political Economy and Hegemony, 1800-1950. By Marilyn Silverman (Toronto, University of Toronto Press, 2001) 566 pp. \$85.00. <i>Journal of Interdisciplinary History</i> , 2003 , 33, 469-470	0	
6	The link between publicly funded health care and compulsory licensing. <i>Cmaj</i> , 2002 , 167, 765-6	3.5	
5	Notes on value for money in healthcare. <i>HealthcarePapers</i> , 2009 , 9, 32-5; discussion 52-5	0.7	
4	When patents are not enough: Supplementary incentives for pharmaceutical innovation 2011 , 39-47		
3	Quando las patentes no bastan: Incentivos adicionales para la innovaci3n farmac3utica 2012 , 47-56		
2	The economic theory of cost-effectiveness thresholds in health: Domestic and international implications. <i>Health Economics (United Kingdom)</i> , 2021 , 30, 1139-1151	2.4	
1	In defense of Canada's drug plan managers. <i>Cmaj</i> , 2018 , 190, E771-E772	3.5	